{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:43Z","timestamp":1790770183159,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.humpath.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T08:22:57Z","timestamp":1709799777000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present"],"prefix":"10.1016","volume":"146","author":[{"given":"Do Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-7880","authenticated-orcid":false,"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.03.002_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2024.03.002_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2024.03.002_bib3","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.humpath.2024.03.002_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2013.08.028","article-title":"PAF and EZH2 induce Wnt\/beta-catenin signaling hyperactivation","volume":"52","author":"Jung","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.humpath.2024.03.002_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.03.002_bib6","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41379-021-00885-9","article-title":"EZH2 expression is associated with inferior overall survival in mantle cell lymphoma","volume":"34","author":"Martinez-Baquero","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.03.002_bib7","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma international prognostic Index in randomized trials of the European mantle-cell lymphoma network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.03.002_bib8","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.humpath.2024.03.002_bib9","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2024.03.002_bib10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/PAS.0000000000002068","article-title":"Blastoid and pleomorphic mantle cell lymphoma demonstrate distinct clinicopathologic and genetic features","volume":"47","author":"Khanlari","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2024.03.002_bib11","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2024.03.002_bib12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.03.002_bib13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.03.002_bib14","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/bcr2214","article-title":"EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer","volume":"10","author":"Pietersen","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2024.03.002_bib15","first-page":"345","article-title":"Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus","volume":"38","author":"Yamada","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2024.03.002_bib16","first-page":"4309","article-title":"Aberrant expression of EZH2 is associated with pathological findings and P53 alteration","volume":"33","author":"Shiogama","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.humpath.2024.03.002_bib17","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1073\/pnas.1719532115","article-title":"An EZH2-mediated epigenetic mechanism behind p53-dependent tissue sensitivity to DNA damage","volume":"115","author":"Kuser-Abali","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2024.03.002_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5858\/2002-126-0456-VOPIAA","article-title":"Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice","volume":"126","author":"Bartley","year":"2002","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2024.03.002_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2024.03.002_bib20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1078-0432.CCR-05-1533","article-title":"Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer","volume":"12","author":"Collett","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.03.002_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899599","article-title":"EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis","volume":"38","author":"Zhao","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.humpath.2024.03.002_bib22","doi-asserted-by":"crossref","first-page":"E962","DOI":"10.1210\/jc.2013-3147","article-title":"PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A","volume":"99","author":"Cui","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.humpath.2024.03.002_bib23","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/cancers14143451","article-title":"TP53-Status-Dependent oncogenic EZH2 activity in pancreatic cancer","volume":"14","author":"Versemann","year":"2022","journal-title":"Cancers"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T21:07:38Z","timestamp":1714684058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":23,"alternative-id":["S0046817724000388"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.03.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}